Talk:Ruthenium diamine complexes

MEDRS

WP:MEDRS requires all biomedical claims to be sourced to good-quality secondary sources. As far as I can ascertain, none of the references in the Developing ruthenium diamine complexes as anticancer drugs section meet those standards. I've therefore removed the following text, which is sourced to primary studies that don't even seem to have a PubMed index:

The excellent stability and water-solubility of ruthenium diamine complexes make them a promising research direction in the field of anti-cancer drug developing. Their high selectivity in the binding with DNA aids the design of more effective anticancer complexes.^[1] Methylation or substitution on en-NH, which prevent the hydrogen bonding, can lead to the loss of cytotoxic activity of the complex toward cancer cell.Cite error: A <ref> tag is missing the closing </ref> (see the help page). Futhermone, ability to target specific cancer cells, such as ovarian cancer cells which are resistant to cisplatin makes ruthenium diamine complexes good alternative or addition to cisplatin, and research shows that these two drugs have very limited cross resistance.^[2]

References

^ Chen H.; Parkinson, J. A.; Morris, R. E.; Sadler, P. J. J. Am. Chem. Soc. 2003, 125, 173-186.
^ Antonarakis, E. S.; Emadi, A.; Ruthenium-based chemotherapeutics: are they ready for prime time?. Cancer chemother. Pharmacy, 2010, 66, 1-9.

Other thoughts would be welcome. --RexxS (talk) 21:21, 16 March 2016 (UTC)[reply]

Proposed move

I propose to move this homework assignment to "Transition metal complexes of diamines". The broader topic could encompass the best parts of this student essay. --Smokefoot (talk) 17:42, 20 March 2016 (UTC)[reply]

[a-1] Chen H.; Parkinson, J. A.; Morris, R. E.; Sadler, P. J. J. Am. Chem. Soc. 2003, 125, 173-186.

[2] Antonarakis, E. S.; Emadi, A.; Ruthenium-based chemotherapeutics: are they ready for prime time?. Cancer chemother. Pharmacy, 2010, 66, 1-9.

[1]

[2]